Sustainability
Guided by our mission” Contributing to Better Health All Over the World” we actively advance sustainability strategies, address stakeholder priorities, and pursue balanced growth across economic, social, and environmental dimensions.
Our Strategy and Approach
Grounded in our core mission to Contribute to Better Health All Over the World, we integrate sustainability into our pharmaceutical expertise by aligning with stakeholder expectations and global standards. Since 2022, we have advanced our efforts through a dedicated Sustainability Committee focused on 5 strategic pillars linked to the UN SDGs.
By setting clear goals and embedding sustainable practices across our operations, we aim to enhance our competitiveness while delivering long-term value to society, the environment, and the broader healthcare ecosystem.
Message from the Chairman and CEO
Bora Pharmaceuticals is a global pharmaceutical group with Contract Development and Manufacturing Organization (CDMO) and global sales capabilities, a forward-looking leadership team and world-class expertise in international regulations and technologies. In the face of rapid growth, we continue to enhance corporate governance and deepen social engagement. We took the lead in incorporating ISO14064 greenhouse gas inventory standards this year; formulated short, medium, and long-term carbon reduction goals; and actively responded to the risks, challenges, and opportunities of sustainable management.
Recognizing ESG as a key to long-term success, we established a Sustainability Committee to integrate our core mission “Contributing to Better Health All Over the World” with stakeholder interests. Guided by 5 strategic pillars aligned with the UN SDGs, we drive sustainable practices that foster economic growth, social impact, and environmental protection, strengthening our role as a responsible pharmaceutical leader.
Bobby Sheng Group CEO & Chairman
Highlights of the Year
Environment
ISO 14064-1
GHG inventory and verification conducted at 8 facilities in 2024, with all sites expected to complete by 2025
Net-Zero
Commitment
Bora Group is committed to achieving net-zero emissions by 2050
Social
Promise of Support™
Specialized services for rare disease communities, ensuring comprehensive support for patients, caregivers, and healthcare providers throughout the treatment process
Sustainability Governance
Reports
Read our latest reports to see the progress we’re making in advancing sustainability across our business.
Our Ratings Overview
Morgan Stanley Capital International ESG Rating
Bora has been awarded an “A” rating by Morgan Stanley Capital International (MSCI) for its Environmental, Social and Governance (ESG) performance. The MSCI ESG Ratings assess a company’s resilience to long-term, industry-specific ESG risks and opportunities, and benchmark it against global peers.
EcoVadis Rating
Bora Group has been recognized as “Committed” by EcoVadis. The EcoVadis assessment covers 21 sustainability criteria across four categories: environment, labor & human rights, ethics, and sustainable procurement. The methodology is aligned with international standards such as the Global Reporting Initiative (GRI), United Nations Global Compact, and the International Labour Organization (ILO).
TWSE's Corporate Governance Evaluation Ranking
Bora has been ranked in the top 6–20% in the Taiwan Stock Exchange (TWSE) Corporate Governance Evaluation. This achievement highlights Bora’s dedication to robust governance and oversight. We have also been newly included in the “Corporate Governance 100 Index” and selected as a constituent of the Fubon Corporate Governance ETF (00692), reflecting the market’s recognition of our governance standards.
FTSE Russell Score
Bora has achieved an ESG rating of 3.5 out of 5 from FTSE Russell, meeting the qualification criteria for inclusion in the FTSE4Good Index Series.
The FTSE4Good Index is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices.